DK3484476T3 - Meclozin-derivater til anvendelse ved forebyggelse og/eller behandling af lidelser associeret med den forårsagede inflammation - Google Patents
Meclozin-derivater til anvendelse ved forebyggelse og/eller behandling af lidelser associeret med den forårsagede inflammation Download PDFInfo
- Publication number
- DK3484476T3 DK3484476T3 DK17745143.2T DK17745143T DK3484476T3 DK 3484476 T3 DK3484476 T3 DK 3484476T3 DK 17745143 T DK17745143 T DK 17745143T DK 3484476 T3 DK3484476 T3 DK 3484476T3
- Authority
- DK
- Denmark
- Prior art keywords
- meclozine
- prevention
- derivatives
- treatment
- disorders associated
- Prior art date
Links
- 206010061218 Inflammation Diseases 0.000 title 1
- OCJYIGYOJCODJL-UHFFFAOYSA-N Meclizine Chemical class CC1=CC=CC(CN2CCN(CC2)C(C=2C=CC=CC=2)C=2C=CC(Cl)=CC=2)=C1 OCJYIGYOJCODJL-UHFFFAOYSA-N 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 208000035475 disorder Diseases 0.000 title 1
- 230000004054 inflammatory process Effects 0.000 title 1
- 230000002265 prevention Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/06—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by halogen atoms or nitro radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
- C07D253/02—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 not condensed with other rings
- C07D253/06—1,2,4-Triazines
- C07D253/065—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members
- C07D253/07—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members with hetero atoms, or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D253/075—Two hetero atoms, in positions 3 and 5
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/203—Retinoic acids ; Salts thereof
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Dermatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP16305912 | 2016-07-13 | ||
PCT/EP2017/067774 WO2018011375A1 (en) | 2016-07-13 | 2017-07-13 | Meclozine derivatives and diclazuril derivatives for use in the prevention and/or the treatment of disorders associated to the inflammation induced by p. acnes |
Publications (1)
Publication Number | Publication Date |
---|---|
DK3484476T3 true DK3484476T3 (da) | 2021-09-27 |
Family
ID=56511498
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK17745143.2T DK3484476T3 (da) | 2016-07-13 | 2017-07-13 | Meclozin-derivater til anvendelse ved forebyggelse og/eller behandling af lidelser associeret med den forårsagede inflammation |
Country Status (13)
Country | Link |
---|---|
US (2) | US11116763B2 (da) |
EP (2) | EP3484476B1 (da) |
JP (1) | JP7274076B2 (da) |
KR (1) | KR20190038828A (da) |
CN (1) | CN109963563A (da) |
AU (1) | AU2017297812A1 (da) |
BR (1) | BR112019000585A2 (da) |
CA (1) | CA3030624A1 (da) |
DK (1) | DK3484476T3 (da) |
ES (1) | ES2897988T3 (da) |
PH (1) | PH12019500076A1 (da) |
SG (1) | SG11201900215YA (da) |
WO (1) | WO2018011375A1 (da) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115414360A (zh) * | 2022-08-30 | 2022-12-02 | 上海交通大学医学院附属仁济医院 | 全反式维甲酸联合抗生素在治疗假体周围感染中的应用 |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1000040B1 (en) * | 1997-07-10 | 2007-06-13 | Janssen Pharmaceutica N.V. | Il-5 inhibiting 6-azauracil derivatives |
BR9914385A (pt) * | 1998-10-08 | 2001-07-17 | New Ace Res Company | Composição útil para o tratamento e prevenção de infecções protozoárias no homem e em animais, e, método de tratamento de uma infecção protozoária no homem e em animais |
US8211916B2 (en) | 2000-06-20 | 2012-07-03 | Wayne State University | N- and O-substituted 4-[2-(diphenylmethoxy)-ethyl]-1-[(phenyl)methyl]piperidine analogs and methods of treating CNS disorders therewith |
KR20050091062A (ko) * | 2003-01-16 | 2005-09-14 | 얀센 파마슈티카 엔.브이. | 디클라주릴을 포함하는 항원충제 조성물 |
WO2005009342A2 (en) | 2003-07-16 | 2005-02-03 | Pharmacia Corporation | Method for the treatment or prevention of dermatological disorders with a cyclooxygenase-2 inhibitor alone and in combination with a dermatological treatment agent and compositions therewith |
BRPI0811102A2 (pt) * | 2007-05-15 | 2014-09-23 | Puretech Ventures | Métodos e composições para tratar condições de pele |
US8784852B2 (en) | 2009-02-27 | 2014-07-22 | Audrey Kunin | Topical skin care composition |
CA2762216C (en) | 2009-05-18 | 2017-07-11 | 3M Innovative Properties Company | Dry powder inhalers |
MX2014002163A (es) | 2011-08-26 | 2014-09-25 | Wockhardt Ltd | Métodos para el tratamiento de desórdenes cardiovasculares. |
ES2606148T3 (es) * | 2011-11-01 | 2017-03-22 | Inopharm Limited | Composición de disgregación oral de agentes antihistamínicos |
WO2017034984A1 (en) * | 2015-08-21 | 2017-03-02 | The Johns Hopkins University | Identification of additional anti-persister activity against borrelia burgdorferi from an fda drug library |
JP2017128541A (ja) | 2016-01-21 | 2017-07-27 | 学校法人東京女子医科大学 | アポトーシス誘導剤 |
-
2017
- 2017-07-13 KR KR1020197003707A patent/KR20190038828A/ko not_active Application Discontinuation
- 2017-07-13 SG SG11201900215YA patent/SG11201900215YA/en unknown
- 2017-07-13 BR BR112019000585A patent/BR112019000585A2/pt not_active Application Discontinuation
- 2017-07-13 US US16/317,091 patent/US11116763B2/en active Active
- 2017-07-13 WO PCT/EP2017/067774 patent/WO2018011375A1/en active Application Filing
- 2017-07-13 JP JP2019501711A patent/JP7274076B2/ja active Active
- 2017-07-13 EP EP17745143.2A patent/EP3484476B1/en active Active
- 2017-07-13 AU AU2017297812A patent/AU2017297812A1/en not_active Abandoned
- 2017-07-13 CA CA3030624A patent/CA3030624A1/en active Pending
- 2017-07-13 EP EP21184745.4A patent/EP3943088A1/en not_active Withdrawn
- 2017-07-13 CN CN201780054743.9A patent/CN109963563A/zh active Pending
- 2017-07-13 ES ES17745143T patent/ES2897988T3/es active Active
- 2017-07-13 DK DK17745143.2T patent/DK3484476T3/da active
-
2019
- 2019-01-11 PH PH12019500076A patent/PH12019500076A1/en unknown
-
2020
- 2020-07-21 US US16/934,055 patent/US11617748B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
EP3484476B1 (en) | 2021-08-25 |
KR20190038828A (ko) | 2019-04-09 |
EP3484476A1 (en) | 2019-05-22 |
PH12019500076A1 (en) | 2019-07-24 |
ES2897988T3 (es) | 2022-03-03 |
JP2019521152A (ja) | 2019-07-25 |
EP3943088A1 (en) | 2022-01-26 |
CN109963563A (zh) | 2019-07-02 |
CA3030624A1 (en) | 2018-01-18 |
BR112019000585A2 (pt) | 2019-07-02 |
US11116763B2 (en) | 2021-09-14 |
JP7274076B2 (ja) | 2023-05-16 |
WO2018011375A1 (en) | 2018-01-18 |
US20200383973A1 (en) | 2020-12-10 |
AU2017297812A1 (en) | 2019-02-07 |
US11617748B2 (en) | 2023-04-04 |
SG11201900215YA (en) | 2019-02-27 |
US20190224191A1 (en) | 2019-07-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK3149019T3 (da) | Cholan-derivater til anvendelse ved behandling og/eller forebyggelse af FXR- og TGR5/GPBAR1-formidlede sygdomme | |
DK3673080T3 (da) | Antisense-oligomerer til behandling af lidelser og sygdomme | |
DK3464266T3 (da) | Substituerede indazoler, der er anvendelige til behandling og forebyggelse af allergiske og/eller inflammatoriske sygdomme hos dyr | |
DK3325509T3 (da) | Anti-tfr antistoffer og deres anvendelse i behandling af proliferative og inflammatoriske lidelser | |
DK3481846T3 (da) | 11-substituerede 24-hydroxysteroler til anvendelse til behandling af nmda-relaterede tilstande | |
DK3395359T3 (da) | Plasminogen til anvendelse til forebyggelse eller behandling af akut trombose og kronisk trombose | |
DK3432899T3 (da) | Anvendelse af probiotika ved behandling og/eller forebyggelse af psoriasis | |
DK3395353T3 (da) | Plasminogen til anvendelse til behandling eller forebyggelse af diabetes-mellitus-nerveskade | |
DK3362449T3 (da) | Sibirilin-derivater til anvendelse til at forebygge og/eller behandle lidelser associeret med cellulær nekroptose | |
DK3303339T3 (da) | Pde9-inhibitorer med imidazotriazinonskelet og imidazopyrazinonskelet til behandling af perifere sygdomme | |
DK3882250T3 (da) | Tetrahydropyranyl-amino-pyrrolopyrimidinon til anvendelse i behandling af btk-medierede forstyrrelser | |
DK3189074T3 (da) | Sammensætninger og metoder til behandling og forebyggelse af inflammation | |
DK3261642T3 (da) | Quinolinderivater til anvendelse ved behandling eller forebyggelse af virusinfektioner | |
DK3273995T3 (da) | Kombineret anvendelse af alginatoligomerer og cftr-modulatoren lumacaftor i behandlingen af tilstande associeret med cftr-dysfunktion | |
DK3442513T3 (da) | Anvendelse af cannabidiolsyre i behandling af autismespektrumforstyrrelse og forbundne forstyrrelser | |
DK3484585T3 (da) | Anvendelse af probiotika ved behandling og/eller forebyggelse af atopisk dermatitis | |
DK3160234T3 (da) | Sammensætning til anvendelse til forebyggelse og behandling af oftalmisk-, hånd- eller fodbiofilmvækst | |
DK3532064T3 (da) | Kombinationsbehandlinger omfattende imidazopyrazinoner til behandlingen af psykiatriske og/eller kognitive lidelser | |
DK3328864T3 (da) | Terapeutiske forbindelser og sammensætninger til behandling af sociale forstyrrelser og stofmisbrugsforstyrrelser | |
DK3153511T3 (da) | 2-acylaminothiazolderivat til anvendelse i forebyggelsen eller behandlingen af blære- og urinvejssygdomme | |
DK3522873T3 (da) | Sammensætninger og fremgangsmåder til behandlingen af xerostomi | |
DK3157532T3 (da) | Fremgangsmåder til behandling og forebyggelse af sygdomme med vaskulær instabilitet | |
DK3373922T3 (da) | Sammensætninger og fremgangsmåder til anvendelse i behandlingen af homocystinuri | |
DK3197556T3 (da) | Sammensætning til forebyggelse og/eller behandling af allergisymptomer | |
DK3247352T3 (da) | Cebranopadol til behandling af smerter hos individer med forringet lever- og/eller forringet nyrefunktion |